Cargando…

Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma

Background: Atezolizumab plus bevacizumab (ATZ + BV) treatment is recommended as the first-line systemic therapy for patients with unresectable hepatocellular carcinoma (u-HCC). This study aimed to investigate the predictive factors of therapeutic response and the continuation of ATZ + BV treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanaka, Takashi, Takata, Kazuhide, Yokoyama, Keiji, Fukuda, Hiromi, Yamauchi, Ryo, Fukunaga, Atsushi, Shakado, Satoshi, Sakisaka, Shotaro, Hirai, Fumihito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324802/ https://www.ncbi.nlm.nih.gov/pubmed/35877241 http://dx.doi.org/10.3390/curroncol29070381

Ejemplares similares

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
por: Ko, Yi-Ling, et al.
Publicado: (2020)

Long-term outcome and eligibility of radiofrequency ablation for hepatocellular carcinoma over 3.0 cm in diameter
por: Tanaka, Takashi, et al.
Publicado: (2023)

Multipolar radiofrequency ablation via three bipolar electrodes with C-arm type X-ray fluoroscopy assistance for hepatocellular carcinoma: An observational study
por: Tanaka, Takashi, et al.
Publicado: (2022)

Two Cases of Rapidly Progressive Fatty Liver Disease due to Pancreatic Exocrine Insufficiency without a History of Surgery
por: Takata, Kazuhide, et al.
Publicado: (2023)

Horizontal Transmission of Hepatitis B Virus Genotype C Among Members of a Wrestling Club in Japan
por: Takata, Kazuhide, et al.
Publicado: (2020)

Hepatitis B Virus Reactivation after Receiving Cancer Chemotherapy under Administration of Leuprorelin Acetate
por: Yamauchi, Ryo, et al.
Publicado: (2020)

Two Cases of Hepatocellular Carcinoma Arising Over 20 Years after a Sustained Virologic Response Following Interferon Therapy for Chronic Hepatitis C
por: Takata, Kazuhide, et al.
Publicado: (2020)

Long-Term Effects of Rifaximin on Patients with Hepatic Encephalopathy: Its Possible Effects on the Improvement in the Blood Ammonia Concentration Levels, Hepatic Spare Ability and Refractory Ascites
por: Yokoyama, Keiji, et al.
Publicado: (2022)

Novel Endoscopic Therapy for Gastric Varices Using Direct Forward-Viewing Endoscopic Ultrasonography
por: Yokoyama, Keiji, et al.
Publicado: (2021)

Hepatitis B virus core–related antigen is useful for surveillance of hepatocellular carcinoma recurrence in a patient with occult hepatitis B virus infection: Case report
por: Yokoyama, Keiji, et al.
Publicado: (2020)

Exploratory Research on the Relationship between Human Gut Microbiota and Portal Hypertension
por: Yokoyama, Keiji, et al.
Publicado: (2020)

Eosinophilic Granuloma of the Liver Mimicking Metastatic Liver Tumor
por: Uchida, Yotaro, et al.
Publicado: (2021)

Male-specific Association between Iron and Lipid Metabolism Changes and Erythroferrone after Hepatitis C Virus Eradication
por: Inomata, Shinjiro, et al.
Publicado: (2021)

Gastroesophageal Varices and Hyperplastic Nodules of the Liver in a Patient with Anorexia Nervosa
por: Takata, Kazuhide, et al.
Publicado: (2021)

Endoscopic treatment or balloon-occluded retrograde transvenous obliteration is safe for patients with esophageal/gastric varices in Child-Pugh class C end-stage liver cirrhosis
por: Yokoyama, Keiji, et al.
Publicado: (2019)

Factors Attenuating Zinc Deficiency Improvement in Direct-Acting Antiviral Agent-Treated Chronic Hepatitis C Virus Infection
por: Ko, Yi-Ling, et al.
Publicado: (2018)

Malnutrition and inflammation status in nonobese patients with inflammatory bowel disease are associated with nonalcoholic fatty liver disease: a retrospective study
por: Nagata, Takahiro, et al.
Publicado: (2023)

Pseudocirrhosis Due to Desmoplastic Response to Chemotherapy in Breast Cancer Liver Metastases
por: Takata, Kazuhide, et al.
Publicado: (2022)

Reduced Glutathione suppresses Oxidative Stress in Nonalcoholic Fatty Liver Disease
por: Irie, Makoto, et al.
Publicado: (2016)

Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study
por: Kudo, Masatoshi, et al.
Publicado: (2023)

Hepatocellular Carcinoma Arising in a Non-cirrhotic Liver with Secondary Hemochromatosis
por: Yamauchi, Ryo, et al.
Publicado: (2018)

Autoimmune Hepatitis with Concomitant Idiopathic Thrombocytopenic Purpura Diagnosed by Transjugular Liver Biopsy
por: Fukuda, Hiromi, et al.
Publicado: (2018)

Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Niizeki, Takashi, et al.
Publicado: (2022)

The Rate of Referral of Hepatitis Virus Carriers to Hepatologists and the Factors Contributing to Referral
por: Takata, Kazuhide, et al.
Publicado: (2017)

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
por: Ahmed, Faiza, et al.
Publicado: (2021)

Changes in the Serum Hepcidin-to-ferritin Ratio with Erythroferrone after Hepatitis C Virus Eradication Using Direct-acting Antiviral Agents
por: Inomata, Shinjiro, et al.
Publicado: (2019)

Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Yano, Shigeki, et al.
Publicado: (2023)

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience
por: Hiraoka, Atsushi, et al.
Publicado: (2021)

A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab
por: Saito, Naoto, et al.
Publicado: (2022)

Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Ando, Yuwa, et al.
Publicado: (2022)

Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France
por: Gaugain, Loïg, et al.
Publicado: (2023)

Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy
por: Tsunemitsu, Ryosuke, et al.
Publicado: (2023)

Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma
por: Kosaka, Yumi, et al.
Publicado: (2022)

Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice
por: Ando, Yuwa, et al.
Publicado: (2021)

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma
por: Zhang, Xin, et al.
Publicado: (2021)

Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
por: Iwamoto, Hideki, et al.
Publicado: (2021)

Corneal Perforation in a Patient Treated with Atezolizumab-Bevacizumab Combination Therapy for Unresectable Hepatocellular Carcinoma
por: Alkharashi, Majed S., et al.
Publicado: (2023)

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma
por: Su, Dan, et al.
Publicado: (2021)

High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma
por: Yang, Hannah, et al.
Publicado: (2023)

Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis
por: Kulkarni, Anand V., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_la2s3bq64uo3931i4f15cnv2o4